

SUPPLEMENTARY MATERIAL

Figure S1: Gating strategy for flow cytometric analysis.




Figure S1_Matucci et al

Example of gating strategy to identify eosinophils and eosinophil sub-populations through flow cytometric analysis. Granulocytes were identified on forward scatter (FSC-A) and side scatter (SSC-A) basis and for CD45 expression. Between CD45 positive cells, eosinophils were identified as Siglec-8 positive/CD16 negative cells. Total eosinophils were divided in two subpopulations based on CD62L expression (CD62L^{bright} and CD62L^{low} eosinophils). A FMO (Fluorescence Minus One) for CD62L panel was shown.

Figure S2: Mepolizumab improves asthma clinical parameters.




Figure S2_Matucci et al

The treatment with mepolizumab improves ACT and ACQ-5 in patients with asthma and CRSwNP. Single patients scores before and after mepolizumab treatment are shown at left; median value with interquartile range of scores are shown at right CRSwNP: Chronic Rhinosinusitis with Nasal Polyp; ACQ-5: Asthma Control Questionnaire-5, ACT: Asthma Control Test. Mann-Whitney U test was used for analysis.